Structure Therapeutics Inc ADR (NASDAQ:GPCR)’s traded shares stood at 0.34 million during the last session, with the company’s beta value hitting -3.41. At the close of trading, the stock’s price was $29.04, to imply a decrease of -1.69% or -$0.5 in intraday trading. The GPCR share’s 52-week high remains $62.74, putting it -116.05% down since that peak but still an impressive 9.68% since price per share fell to its 52-week low of $26.23. The company has a valuation of $1.66B, with an average of 1.1 million shares in intraday trading volume over the past 10 days and average of 817.02K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Structure Therapeutics Inc ADR (GPCR), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give GPCR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.16.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Structure Therapeutics Inc ADR (NASDAQ:GPCR) trade information
After registering a -1.69% downside in the last session, Structure Therapeutics Inc ADR (GPCR) has traded red over the past five days. The 5-day price performance for the stock is -3.10%, and -13.93% over 30 days. With these gigs, the year-to-date price performance is -28.75%. Short interest in Structure Therapeutics Inc ADR (NASDAQ:GPCR) saw shorts transact 10.44 million shares and set a 15.69 days time to cover.
The extremes give us $86 and $118 for target low and target high price respectively. As such, GPCR has been trading -306.34% off suggested target high and -196.14% from its likely low.
Structure Therapeutics Inc ADR (GPCR) estimates and forecasts
Looking at statistics comparing Structure Therapeutics Inc ADR share performance against respective industry, we note that the company has underperformed competitors. Structure Therapeutics Inc ADR (GPCR) shares are -26.05% down over the last 6 months, with its year-to-date growth rate lower than industry average at -1.23% against 16.60%.
GPCR Dividends
Structure Therapeutics Inc ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Structure Therapeutics Inc ADR (NASDAQ:GPCR)’s Major holders
Structure Therapeutics Inc ADR insiders hold 4.84% of total outstanding shares, with institutional holders owning 107.26% of the shares at 112.72% float percentage. In total, 107.26% institutions holds shares in the company.
We also have Smallcap World Fund and Vanguard Specialized-Health Care Fund as the top two Mutual Funds with the largest holdings of the Structure Therapeutics Inc ADR (GPCR) shares. Going by data provided on Sep 30, 2024 , Smallcap World Fund holds roughly 4.32 shares. This is just over 7.55% of the total shares, with a market valuation of $125.53 million. Data from the same date shows that the other fund manager holds a little less at 4.04, or 7.06% of the shares, all valued at about 117.34 million.
